Gedeon Richter Looks to Dendrite to Enhance its Sales Force Effectiveness Solution
June 13 2006 - 8:00AM
Business Wire
Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of
pharmaceutical industry solutions, today announced the expansion of
its relationship with Gedeon Richter, a leading pharmaceutical
company in Central and Eastern Europe. Dendrite will provide Gedeon
Richter's Russian Federation based division with its sales force
effectiveness (SFE) solution, expanding on a previous agreement to
enhance sales force effectiveness for the company's divisions in
Poland, Romania and the Czech Republic. With the addition of this
division, Dendrite's SFE solution will now assist a total of 1000
of Gedeon Richter's representatives with core sales force
effectiveness enabling functions, including call reporting,
targeting, advanced data sharing, data analysis and decision
support, event management, territory planning and scheduling. "We
required a solution that gave us the ability to optimize sales
activities across sales forces in multiple countries, with the
versatility to adapt to our growing business. Dendrite was an
obvious choice because it offered the most flexible and scalable
solution -- supporting strategic sales forces of under 100 users to
more than 1000. Furthermore, since the solution can be deployed in
multiple countries, it gives us the ability to easily share
information on a common platform across all of our Central and
Eastern European regions," said Deputy Commercial Director Beata
Taligas at Gedeon Richter's Budapest headquarters. Designed by
Dendrite's experts specifically to enhance usability for
pharmaceutical industry sales forces, Dendrite's SFE solution
optimizes and coordinates promotional activities across sales
teams, improves communications, and streamlines new product
launches. "We are delighted to have extended our offering to Gedeon
Richter, at a time during which the industry is increasingly
recognizing the value of solutions that are easy to use and based
on actual business process flow. Dendrite SFE solutions are built
specifically for the pharmaceutical industry and we look forward to
continuing to strengthen the relationship with Gedeon through
adding valuable support," said Mario Mauri, president, Dendrite
Europe. About Dendrite Founded in 1986, Dendrite International
(NASDAQ: DRTE) enables sales, marketing, clinical and compliance
solutions for the global, pharmaceutical industry. The Company's
clients are located in more than 50 countries and include the
world's top 20 pharmaceutical companies. For more information,
please visit www.dendrite.com. About Gedeon Richter Gedeon Richter
Ltd carries out research, development, manufacture and marketing of
human finished drugs, active substances and intermediates. The
Company manufactures about one hundred kinds of pharmaceuticals in
more than 170 presentations. Among its products are original,
generic and licensed preparations. Products cover numerous
therapeutic areas, with special emphasis on the production and
development of drugs for the central nervous system, as well as
anti-ulcer agents, cardiovascular and gastrointestinal preparations
and oral contraceptives. Note: Dendrite is a registered trademark
of Dendrite International, Inc. This document may contain
forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and
similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties,
including risks which may result from our dependence on the
pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our
solutions; our fixed expenses in relation to fluctuating revenues
and variations in customers' budget cycles; dependence on certain
major customers; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
successful and timely development and introduction of new products
and versions; rapid technological changes; increased competition;
international operations; integrating the entities we acquire; our
ability to effectively manage our growth; the protection of our
proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand
for Internet-related products and services; the ability of our
third party vendors to respond to technological change; our ability
to maintain our relationships with third-party vendors; less
favorable than anticipated results from strategic relationships;
dependence of data solutions on strategic relationships; events
which may affect the U.S. and world economies; and catastrophic
events which could negatively affect our information technology
infrastructure. Other important factors that should be reviewed and
carefully considered are included in the company's 10-K, 10-Qs, and
other reports filed with the SEC. Actual results may differ
materially. The company assumes no obligation for updating any such
forward-looking statements to reflect actual results, changes in
assumptions or other changes affecting such forward-looking
statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024